Halozyme Therapeutics (HALO) 9.82 $HALO
Halozyme Therapeutics To Host Analyst And Investor Meeting
PR Newswire - Tue Dec 30, 8:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced it will be hosting a meeting for analysts and investors in New York on Wednesday, January 7, 2015 at 10:00 a.m. ET/ 7:00 a.m. PT. During the meeting, Halozyme's senior management and a physician expert will discuss the following topics:
HALO: 9.82 (+0.17)
Halozyme's PEGPH20 tagged an Orphan Drug in Europe
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 9:31AM CST
HALO: 9.82 (+0.17)
Halozyme Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer
PR Newswire - Fri Dec 19, 7:30AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA), has designated PEGylated recombinant human hyaluronidase (PEGPH20) an orphan medicinal product for the treatment of pancreatic cancer. Halozyme is currently conducting a Phase 2 study on the treatment of metastatic pancreatic cancer with PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE®). In October 2014, the Company disclosed that the U.S. Food and Drug Administration also granted Orphan Drug designation for PEGPH20 for the treatment of pancreatic cancer.
HALO: 9.82 (+0.17)
Halozyme Up on Collaboration and Licensing Deal with J&J - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 5:48PM CST
Shares of Halozyme (HALO) jumped after announcing a worldwide collaboration and license agreement with Johnson & Johnson (JNJ).
JNJ: 104.52 (-0.05), HALO: 9.82 (+0.17), PFE: 31.33 (+0.18), AMGN: 159.89 (+0.60)
Deal Street: Analyst Coverage on Visteon, Halozyme, Coca-Cola, Groupon and Barrick Gold
PR Newswire - Thu Dec 18, 8:30AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations including Visteon (NYSE: VC), Halozyme (NASDAQ: HALO), Coca-Cola (NYSE: KO), Groupon (NASDAQ: GRPN), and Barrick Gold (NYSE: ABX). Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
KO: 42.14 (-0.08), VC: 105.80 (-1.06), HALO: 9.82 (+0.17), ABX: 10.91 (+0.16), GRPN: 8.02 (-0.24)
Janssen Biotech licenses Halozyme's Enhanze technology
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:30AM CST
JNJ: 104.52 (-0.05), HALO: 9.82 (+0.17)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:13AM CST
CERS: 6.51 (+0.27), FRO: 2.51 (unch), KNDI: 13.04 (-0.97), GFI: 4.65 (+0.12), CLF: 7.03 (-0.11), NVGN: 2.16 (+0.08), ASPX: 53.11 (+0.63), DRIV: 24.86 (+0.13), SID: 1.95 (-0.13), HALO: 9.82 (+0.17), VOLC: 17.86 (-0.02), POZN: 7.88 (-0.12), ICLD: 2.98 (+0.06), TASR: 26.51 (+0.03), DGLY: 15.46 (+0.14), SBGL: 7.52 (-0.05)
Halozyme Therapeutics Enters A Global Collaboration With Janssen To Develop And Commercialize Subcutaneous Products Using ENHANZE(TM) Technology
PR Newswire - Wed Dec 17, 8:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has entered into a worldwide Collaboration and License Agreement with Janssen Biotech, Inc. (Janssen) for the purpose of developing and commercializing products combining proprietary Janssen compounds with Halozyme's ENHANZE(TM) technology. ENHANZE is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20) that temporarily modifies hyaluronan, a component of the extracellular matrix, to aid in the dispersion and absorption of other injected therapeutic drugs.
HALO: 9.82 (+0.17)
United States Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry Analytics 2014-2021 - Market to reach $39.5 billion by 2021
M2 - Mon Dec 15, 8:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/s847lc/vaccines_skin) has announced the addition of Plunkett Research Ltd's new report "Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.) to reach $39.5 billion by 2021 Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked - Anika Therapeutics Inc - CSL Behring LLC - Emergent BioSolutions Inc - Halozyme Therapeutics Inc - LifeCell Corporation - Lifecore Biomedical Inc - MiMedx Group Inc - Organogenesis Inc - RTI Biologics Inc - Zoetis Inc For more information visit http://www.researchandmarkets.com/research/s8...cines_skin Source: Plunkett Research Ltd
ZTS: 43.31 (+0.28), RTIX: 5.15 (-0.05), HALO: 9.82 (+0.17), EBS: 26.90 (-0.33), ANIK: 39.76 (-0.98), MDXG: 9.74 (-1.79)
Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Fri Dec 12, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, December 11, 2014, the NASDAQ Composite ended at 4,708.16, up 0.52%, the Dow Jones Industrial Average advanced 0.36%, to finish the day at 17,596.34, and the S&P 500 closed at 2,035.33, up 0.45%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index also advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
BLUE: 91.26 (-0.46), BIIB: 342.01 (+2.56), ACAD: 31.15 (-0.60), NBIX: 22.84 (+0.50), HALO: 9.82 (+0.17)
Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting
PR Newswire - Fri Dec 12, 7:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the 37th Annual San Antonio Breast Cancer Symposium (SABCS) today. The first of the presentations includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of immune-based cancer therapy such as monoclonal antibodies (mAbs). The second presentation includes additional supportive preclinical information on the utility of hyaluronan (HA) as a potential biomarker for cancer treatments. PEGPH20 is an investigational PEGylated form of rHuPH20 under development by Halozyme. PEGPH20 degrades the hyaluronan coating that may provide a supportive environment in many solid tumors.
HALO: 9.82 (+0.17)
Can Pfizer’s Cholesterol Drug Catch Up To The Competition?
Leo Sun, The Motley Fool - Motley Fool - Thu Dec 11, 6:28AM CST
Pfizer 's revenue has dramatically declined since 2011, the year Lipitor went off patent in the U.S. The blockbuster cholesterol drug, which already lost exclusivity in several markets at the time, still generated sales of $9.6 billion that year,...
HALO: 9.82 (+0.17), PFE: 31.33 (+0.18), AMGN: 159.89 (+0.60), SNY: 45.52 (-0.09), REGN: 410.16 (-0.09)
Halozyme Therapeutics - Buy The Drug Delivery Platform And Get A Cancer Drug For Free
Small Pharma Analyst - at Seeking Alpha - Tue Dec 09, 10:56AM CST
HALO: 9.82 (+0.17)
Halozyme Therapeutics To Present At The 25th Annual Oppenheimer Healthcare Conference
PR Newswire - Wed Dec 03, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 25th Annual Oppenheimer Healthcare Conference in New York on Wednesday, December 10, 2014 at 1:00 p.m. ET/10:00 a.m. PT. David Ramsay, Vice President and Chief Financial Officer, will provide a corporate overview.
HALO: 9.82 (+0.17)
Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
PR Newswire - Tue Nov 25, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014 at 1:00 p.m. EDT/10:00 a.m. PDT. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
HALO: 9.82 (+0.17)
Halozyme Therapeutics Earnings Review: 14 Days after Announcement Shares Down 8.6% (HALO)
Comtex SmarTrend(R) - Mon Nov 24, 9:18AM CST
When Halozyme Therapeutics (NASDAQ:HALO) reported earnings 14 days ago on November 10th, 2014, analysts, on average, expected the company to report a loss of $0.14 on sales of $16.5 million. Halozyme Therapeutics actually reported a loss of $0.16 per share on sales of $14.6 million, missing EPS estimates by $0.02 and missing revenue estimates by $1.9 million. Since the company's report, shares of Halozyme Therapeutics have fallen from $9.32 to $8.52, representing a loss of 8.6% in the past 14 days.
HALO: 9.82 (+0.17)
Halozyme Therapeutics Earnings Review: 7 Days after Announcement Shares Down 8.4% (HALO)
Comtex SmarTrend(R) - Mon Nov 17, 3:10PM CST
A week ago on November 10th, 2014 Halozyme Therapeutics (NASDAQ:HALO) reported earnings and analysts, on average, expected a loss of $0.14 on sales of $16.5 million. The company actually reported a loss of $0.16 per share on sales of $14.6 million, missing EPS estimates by $0.02 and missing revenue estimates by $1.9 million. Since the company's report, shares of Halozyme Therapeutics have fallen from $9.32 to $8.54, representing a loss of 8.4% in the past 7 days.
HALO: 9.82 (+0.17)
Halozyme Therapeutics (HALO) Stock Is Slipping Today on Weak Third Quarter Earnings
at The Street - Tue Nov 11, 10:42AM CST
Halozyme Therapeutics (HALO) stock is down after the company reported lower than expected third quarter earnings late Monday.
HALO: 9.82 (+0.17)
Halozyme net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 7:55AM CST
HALO: 9.82 (+0.17)
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:33PM CST
HALO: 9.82 (+0.17)
Halozyme Therapeutics To Host Analyst And Investor Meeting
PR Newswire - Tue Dec 30, 8:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced it will be hosting a meeting for analysts and investors in New York on Wednesday, January 7, 2015 at 10:00 a.m. ET/ 7:00 a.m. PT. During the meeting, Halozyme's senior management and a physician expert will discuss the following topics:
HALO: 9.82 (+0.17)
Halozyme's PEGPH20 tagged an Orphan Drug in Europe
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 9:31AM CST
HALO: 9.82 (+0.17)
Halozyme Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer
PR Newswire - Fri Dec 19, 7:30AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA), has designated PEGylated recombinant human hyaluronidase (PEGPH20) an orphan medicinal product for the treatment of pancreatic cancer. Halozyme is currently conducting a Phase 2 study on the treatment of metastatic pancreatic cancer with PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE®). In October 2014, the Company disclosed that the U.S. Food and Drug Administration also granted Orphan Drug designation for PEGPH20 for the treatment of pancreatic cancer.
HALO: 9.82 (+0.17)
Halozyme Up on Collaboration and Licensing Deal with J&J - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 5:48PM CST
Shares of Halozyme (HALO) jumped after announcing a worldwide collaboration and license agreement with Johnson & Johnson (JNJ).
JNJ: 104.52 (-0.05), HALO: 9.82 (+0.17), PFE: 31.33 (+0.18), AMGN: 159.89 (+0.60)
Deal Street: Analyst Coverage on Visteon, Halozyme, Coca-Cola, Groupon and Barrick Gold
PR Newswire - Thu Dec 18, 8:30AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations including Visteon (NYSE: VC), Halozyme (NASDAQ: HALO), Coca-Cola (NYSE: KO), Groupon (NASDAQ: GRPN), and Barrick Gold (NYSE: ABX). Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
KO: 42.14 (-0.08), VC: 105.80 (-1.06), HALO: 9.82 (+0.17), ABX: 10.91 (+0.16), GRPN: 8.02 (-0.24)
Janssen Biotech licenses Halozyme's Enhanze technology
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:30AM CST
JNJ: 104.52 (-0.05), HALO: 9.82 (+0.17)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:13AM CST
CERS: 6.51 (+0.27), FRO: 2.51 (unch), KNDI: 13.04 (-0.97), GFI: 4.65 (+0.12), CLF: 7.03 (-0.11), NVGN: 2.16 (+0.08), ASPX: 53.11 (+0.63), DRIV: 24.86 (+0.13), SID: 1.95 (-0.13), HALO: 9.82 (+0.17), VOLC: 17.86 (-0.02), POZN: 7.88 (-0.12), ICLD: 2.98 (+0.06), TASR: 26.51 (+0.03), DGLY: 15.46 (+0.14), SBGL: 7.52 (-0.05)
Halozyme Therapeutics Enters A Global Collaboration With Janssen To Develop And Commercialize Subcutaneous Products Using ENHANZE(TM) Technology
PR Newswire - Wed Dec 17, 8:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has entered into a worldwide Collaboration and License Agreement with Janssen Biotech, Inc. (Janssen) for the purpose of developing and commercializing products combining proprietary Janssen compounds with Halozyme's ENHANZE(TM) technology. ENHANZE is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20) that temporarily modifies hyaluronan, a component of the extracellular matrix, to aid in the dispersion and absorption of other injected therapeutic drugs.
HALO: 9.82 (+0.17)
United States Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry Analytics 2014-2021 - Market to reach $39.5 billion by 2021
M2 - Mon Dec 15, 8:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/s847lc/vaccines_skin) has announced the addition of Plunkett Research Ltd's new report "Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.) to reach $39.5 billion by 2021 Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked - Anika Therapeutics Inc - CSL Behring LLC - Emergent BioSolutions Inc - Halozyme Therapeutics Inc - LifeCell Corporation - Lifecore Biomedical Inc - MiMedx Group Inc - Organogenesis Inc - RTI Biologics Inc - Zoetis Inc For more information visit http://www.researchandmarkets.com/research/s8...cines_skin Source: Plunkett Research Ltd
ZTS: 43.31 (+0.28), RTIX: 5.15 (-0.05), HALO: 9.82 (+0.17), EBS: 26.90 (-0.33), ANIK: 39.76 (-0.98), MDXG: 9.74 (-1.79)
Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Fri Dec 12, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, December 11, 2014, the NASDAQ Composite ended at 4,708.16, up 0.52%, the Dow Jones Industrial Average advanced 0.36%, to finish the day at 17,596.34, and the S&P 500 closed at 2,035.33, up 0.45%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index also advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
BLUE: 91.26 (-0.46), BIIB: 342.01 (+2.56), ACAD: 31.15 (-0.60), NBIX: 22.84 (+0.50), HALO: 9.82 (+0.17)
Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting
PR Newswire - Fri Dec 12, 7:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the 37th Annual San Antonio Breast Cancer Symposium (SABCS) today. The first of the presentations includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of immune-based cancer therapy such as monoclonal antibodies (mAbs). The second presentation includes additional supportive preclinical information on the utility of hyaluronan (HA) as a potential biomarker for cancer treatments. PEGPH20 is an investigational PEGylated form of rHuPH20 under development by Halozyme. PEGPH20 degrades the hyaluronan coating that may provide a supportive environment in many solid tumors.
HALO: 9.82 (+0.17)
Can Pfizer’s Cholesterol Drug Catch Up To The Competition?
Leo Sun, The Motley Fool - Motley Fool - Thu Dec 11, 6:28AM CST
Pfizer 's revenue has dramatically declined since 2011, the year Lipitor went off patent in the U.S. The blockbuster cholesterol drug, which already lost exclusivity in several markets at the time, still generated sales of $9.6 billion that year,...
HALO: 9.82 (+0.17), PFE: 31.33 (+0.18), AMGN: 159.89 (+0.60), SNY: 45.52 (-0.09), REGN: 410.16 (-0.09)
Halozyme Therapeutics - Buy The Drug Delivery Platform And Get A Cancer Drug For Free
Small Pharma Analyst - at Seeking Alpha - Tue Dec 09, 10:56AM CST
HALO: 9.82 (+0.17)
Halozyme Therapeutics To Present At The 25th Annual Oppenheimer Healthcare Conference
PR Newswire - Wed Dec 03, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 25th Annual Oppenheimer Healthcare Conference in New York on Wednesday, December 10, 2014 at 1:00 p.m. ET/10:00 a.m. PT. David Ramsay, Vice President and Chief Financial Officer, will provide a corporate overview.
HALO: 9.82 (+0.17)
Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
PR Newswire - Tue Nov 25, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014 at 1:00 p.m. EDT/10:00 a.m. PDT. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
HALO: 9.82 (+0.17)
Halozyme Therapeutics Earnings Review: 14 Days after Announcement Shares Down 8.6% (HALO)
Comtex SmarTrend(R) - Mon Nov 24, 9:18AM CST
When Halozyme Therapeutics (NASDAQ:HALO) reported earnings 14 days ago on November 10th, 2014, analysts, on average, expected the company to report a loss of $0.14 on sales of $16.5 million. Halozyme Therapeutics actually reported a loss of $0.16 per share on sales of $14.6 million, missing EPS estimates by $0.02 and missing revenue estimates by $1.9 million. Since the company's report, shares of Halozyme Therapeutics have fallen from $9.32 to $8.52, representing a loss of 8.6% in the past 14 days.
HALO: 9.82 (+0.17)
Halozyme Therapeutics Earnings Review: 7 Days after Announcement Shares Down 8.4% (HALO)
Comtex SmarTrend(R) - Mon Nov 17, 3:10PM CST
A week ago on November 10th, 2014 Halozyme Therapeutics (NASDAQ:HALO) reported earnings and analysts, on average, expected a loss of $0.14 on sales of $16.5 million. The company actually reported a loss of $0.16 per share on sales of $14.6 million, missing EPS estimates by $0.02 and missing revenue estimates by $1.9 million. Since the company's report, shares of Halozyme Therapeutics have fallen from $9.32 to $8.54, representing a loss of 8.4% in the past 7 days.
HALO: 9.82 (+0.17)
Halozyme Therapeutics (HALO) Stock Is Slipping Today on Weak Third Quarter Earnings
at The Street - Tue Nov 11, 10:42AM CST
Halozyme Therapeutics (HALO) stock is down after the company reported lower than expected third quarter earnings late Monday.
HALO: 9.82 (+0.17)
Halozyme net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 7:55AM CST
HALO: 9.82 (+0.17)
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:33PM CST
HALO: 9.82 (+0.17)
